The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

Cancer Policy

FDA releases 10 guiding principles for AI use in drug development

FDA to increase regulatory flexibility for development of cell and gene therapies

OpenAI launches ChatGPT Health to analyze medical records

Federal judge grants preliminary injunction to restore $12M in grants to AAP

NIH agrees to review hundreds of denied or shelved grant applications

House passes three-year extension of ACA subsidies with bipartisan support

Clinical Roundup

Tecvayli monotherapy demonstrates superior PFS and OS vs. standard of care in MM

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Mayo develops AI tool that predicts prostate cancer recurrence

LSU researchers identify proteins linked to prostate cancer

In The Clinic

A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

Trials & Tribulations
Free
Regulatory News
Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account